Rare Cancers, Common Need

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Sandip Patel
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
Young Kwang Chae
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Sandip Patel
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
Young Kwang Chae
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login